Latest News

The wet lab streak continues: Prediction from our AI+QQ in silico process showing actual in vitro inhibition effect on another specific human protease.

Latest from the wet labs. Prediction from our AI+QQ in-silico process showing actual in vitro inhibition effect on CNS ion channels (our foray into CNS indications).

More progress from wet labs. Prediction from our AI+QQ in-silico process showing actual in vitro potentiation effect on cardiac ion channel (our first foray into a cardiac indication). This is #2 of 2 potentiation candidates that showed effect.

Next off the wet lab – Prediction from our AI+QQ in-silico predicted process showing actual in vitro potentiation effect on cardiac ion channel (our first foray into a cardiac indication). This is #1 of 2 potentiation candidates that showed effect.

Feeling like we are on a streak now. From the wet labs – Prediction from our AI+QQ in silico process showing actual in vitro potentiation effect on specific human protease.

Our latest progress from the wet labs. Prediction from our AI+QQ in-silico predicted process showing actual in vitro potentiation effect against specific human apoptotic protease. 

We are excited to have been selected to present our OIRD countermeasure results at the NIH/NIDA/BARDA conference.

Prediction from our AI+QQ in-silico predicted process showing actual in vitro inhibition effect against yet another human protease. 

More results from the wet labs -- here our AI+QQ in-silico process is predicting the actual in vitro effect potentiation against an ion channel (our first foray into a CNS indication).

ARIScience presented confirmations of multiple in vitro protease and ion channel inhibition candidates as evidence of progress with our AI+QQ Methodology.

A recent outcome from our wet lab experiments.  Prediction from our AI+QQ in-silico process showing actual in vitro effect (green, blue, purple) against a specific human protease. 

The paper resulting from the "New COVID-19 Variants - Post Challenge Analysis" challenge was accepted and will soon be published by the Cambridge University Press Journal of Clinical and Translational Science

ARIScience continues engage in groundbreaking work on Dengue protein interruption

ARIScience's research on COVID-19's impact on diabetic patients reveals statistically significant associations between metformin use and less severe outcomes from COVID-19 compared to SU use, but not compared to DPP4i use.

ARIScience and University of North Dakota signed a research collaboration agreement on the use of the UND Computational Research Center’s (UND CRC) high performance computing (HPC) system to further ARIScience’s SARS-CoV-2 protein interruption research.

ARIScience recognized by BARDA in pediatric COVID-19 severity prediction AI challenge.

M2D2 selects ARIScience as a "Runner Up" in their 2022 challenge focused on identifying and rewarding disruptive companies in the medical technology and biotechnology industries.

Bridges helps identify meds for other conditions that associate with lower death rates in COVID-19 patients

COVID-19 HPC Consortium and XSEDE provides access to multiple super-computing centers to speed along ARI's breakthrough COVID-19 research.

EHR data from the N3C Data Enclave were used to produce a recent preprint published in medRxiv authored by ARIScience's Joy Alamgir, et al.